🇺🇸 FDA
Pipeline program

ZF874

ZF-0101

Phase 1 small_molecule terminated

Quick answer

ZF874 for Alpha1 Anti-Trypsin Deficiency is a Phase 1 program (small_molecule) at Centessa Pharmaceuticals plc with 1 ClinicalTrials.gov record(s).

Program details

Company
Centessa Pharmaceuticals plc
Indication
Alpha1 Anti-Trypsin Deficiency
Phase
Phase 1
Modality
small_molecule
Status
terminated

Clinical trials